
Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
Take-home ketamine lozenges, also called troches, are compounded sublingual or buccal tablets that dissolve under the tongue or against the cheek between telehealth visits. No federal agency publishes a uniform monitoring checklist for this product, because the U.S. Food and Drug Administration (FDA) has not approved any ketamine lozenge for depression, anxiety, or any other mental health condition. Ketamine is a Drug Enforcement Administration (DEA) Schedule III controlled substance, approved only as a general anesthetic; its use for mood disorders is off-label. The monitoring you encounter depends entirely on the individual prescribing practice. That is a sharp contrast to esketamine (Spravato), the only ketamine-related drug with FDA approval for treatment-resistant depression, which bars take-home use entirely under a mandated monitoring program. Here is what oversight typically looks like for take-home lozenges and what to confirm before you start one.
Quick Answer
There is no single federal standard for monitoring take-home ketamine lozenges because the FDA has not approved any ketamine product for home use in mental health care. Prescribing clinics set their own protocols, which commonly include a baseline cardiovascular and psychiatric screening, blood pressure checks around initial doses, a required support person during early sessions, a multi-hour driving restriction, and periodic telehealth check-ins. Esketamine (Spravato) is different: it carries an FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) that requires in-clinic dosing with at least two hours of observed monitoring and prohibits take-home use entirely.
Why Monitoring Rules Vary by Prescriber
Esketamine's REMS program, described in more detail in Spravato REMS requirements explained, was built into its FDA approval: certified healthcare settings must observe patients for blood pressure changes and dissociation for at least two hours after each dose, and the drug cannot leave the facility. Generic ketamine lozenges have no equivalent federal program because they are prescribed off-label, meaning a clinician is using an approved anesthetic for an unapproved purpose based on clinical judgment rather than an FDA-reviewed protocol. The scope and consistency of safety oversight for this off-label use is covered further in compounded ketamine safety oversight.
Prescribing controlled substances like ketamine through telehealth also sits under separate federal rules. The Ryan Haight Act generally requires an in-person medical evaluation before a controlled substance can be prescribed via telemedicine, though the DEA has repeatedly extended pandemic-era flexibilities that allow some exceptions. Because this policy area has shifted multiple times since 2023, readers should confirm the current rule directly with the DEA Diversion Control Division or their prescriber rather than assume a past rule still applies in 2026.
Questions to Ask Before Starting Take-Home Treatment
- Ask whether a support person is required to be present during your first several doses
- Confirm the blood pressure and heart rate monitoring schedule for your initial doses
- Clarify the driving and machinery-restriction window after each dose
- Ask how often you will have telehealth or in-person follow-up visits
- Ask about bladder symptom screening if you will dose more than a few times per month
- Confirm how many lozenges are dispensed per prescription and the refill process
What Home Monitoring Commonly Covers
Because a sublingual or buccal lozenge bypasses much of first-pass metabolism (described in the first-pass metabolism glossary entry), absorption and onset differ from an oral capsule, which affects how soon side effects can appear. You can compare that timing in ketamine onset time by route of administration and peak plasma concentration by route, and see how the buccal route specifically behaves in buccal ketamine administration absorption and clinical use.
Clinics that prescribe take-home lozenges for repeated or long-term use commonly add two monitoring items beyond the initial dosing visit: periodic urinary symptom screening, since frequent ketamine exposure has been linked to bladder irritation in research summarized in ketamine-induced cystitis and bladder toxicity research, and liver function checks for patients dosing several times per week. Neither is mandated by a federal rule; both reflect clinical judgment about cumulative exposure.
Compare evidence and options
Compare ketamine with other treatment paths using neutral explainers.
Compare optionsA prescription for take-home ketamine means the treatment is FDA-approved for my condition.
The FDA has approved only esketamine (Spravato) for treatment-resistant depression. Oral and sublingual ketamine lozenges are prescribed off-label, so monitoring rests on the clinician's protocol rather than an FDA-mandated program.
Take-home ketamine doesn't need blood pressure monitoring since it's not given in a clinic.
Ketamine can raise blood pressure and heart rate regardless of route. Clinical guidance commonly calls for a baseline cardiovascular check and monitoring during initial doses even when the medication is self-administered at home.
No Uniform Monitoring Standard
There is no federal minimum monitoring standard specific to take-home ketamine lozenges, so protocols vary between telehealth practices and clinics. Ask your prescriber directly what their protocol includes, in writing, before your first dose.
This article is educational and not a substitute for medical advice. Whether a take-home lozenge, an in-clinic infusion, or Spravato fits your situation depends on your diagnosis, medical history, and access to supervision between doses. Discuss these specifics with a licensed prescriber before starting any ketamine-based treatment.
Compare Ketamine Delivery Methods
See how take-home lozenges stack up against IV, IM, and esketamine on supervision, onset, and monitoring.
Frequently Asked Questions
No. Only esketamine (Spravato) holds FDA approval, specifically for treatment-resistant depression, and it cannot be taken home. Oral and sublingual ketamine lozenges are prescribed off-label.
This varies by clinic. Many practices schedule follow-ups every two to four weeks initially, tapering to monthly, but there is no federally mandated schedule, so confirm the specific cadence with your prescriber.
Most clinics instruct patients not to drive for several hours after dosing because of dissociative effects. Confirm the exact restriction window with your prescriber, since it is set by the clinic rather than a federal rule.
Spravato requires in-clinic administration with at least two hours of observed monitoring under its FDA-mandated REMS program, detailed in Spravato REMS requirements explained. Take-home lozenges rely on clinic-specific home protocols because no equivalent federal program covers them.
Share
Related Reading
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.


